Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find ...

Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability ...

The companies ADARx Pharmaceuticals, Electra Therapeutics, and Enveda bagged the biggest biotech funding rounds overall in ...

Brain biomarkers were long hard to pin down. See how new Parkinson's and Alzheimer's biomarkers are changing that.

As BIOSPAIN 2026 comes to end, delve into what as been at the center of this edition's discussion: what comes after we have ...

Learn how to choose and integrate automated liquid handling solutions while overcoming challenges and supporting flexible lab ...

PMOS, formerly PCOS, still has no approved dedicated drug. Discover the new PMOS treatments in development, from GLP-1s to ...

Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...

Discover biotech and big pharma’s emerging interest in developing macrocyclic drugs for cardiometabolic diseases.

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...